A Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Infusing HSC835 in Patients With Hematological Malignancies Undergoing UCB Transplantation Using a Non-myeloablative Conditioning Regimen

Trial Profile

A Single-arm, Open-label Study to Evaluate the Safety and Tolerability of Infusing HSC835 in Patients With Hematological Malignancies Undergoing UCB Transplantation Using a Non-myeloablative Conditioning Regimen

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Aug 2017

At a glance

  • Drugs MGTA 456 (Primary) ; Cord blood stem cell therapy
  • Indications Haematological malignancies
  • Focus Adverse reactions
  • Acronyms UCBT
  • Sponsors Novartis
  • Most Recent Events

    • 21 Sep 2016 Status changed from active, no longer recruiting to completed.
    • 24 Mar 2016 Planned End Date changed from 1 Nov 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
    • 24 Mar 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Aug 2016 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top